The experience of using omalizumab biosimilar in patients with atopic bronchial asthma and clinically significant sensitization to aeroallergens in the Republic of Uzbekistan

Authors
Category Primary study
JournalImmunologiya
Year 2025
This article has no abstract
Epistemonikos ID: 061faedcb70a26ea6e8d6b91f04d495ea9f33719
First added on: Aug 02, 2025